Axsome Therapeutics, Inc. (LON:0HKF)
102.93
-0.13 (-0.13%)
At close: Aug 4, 2025
Axsome Therapeutics Employees
Axsome Therapeutics had 683 employees as of December 31, 2024. The number of employees increased by 138 or 25.32% compared to the previous year.
Employees
683
Change (1Y)
138
Growth (1Y)
25.32%
Revenue / Employee
$529,026
Profits / Employee
-$263,854
Market Cap
4.00B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 683 | 138 | 25.32% |
Dec 31, 2023 | 545 | 162 | 42.30% |
Dec 31, 2022 | 383 | 275 | 254.63% |
Dec 31, 2021 | 108 | 48 | 80.00% |
Dec 31, 2020 | 60 | 15 | 33.33% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,382 |
Axsome Therapeutics News
- 11 days ago - Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy - Seeking Alpha
- 15 days ago - Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - GlobeNewsWire
- 27 days ago - Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 - GlobeNewsWire
- 4 weeks ago - Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 - GlobeNewsWire
- 6 weeks ago - Axsome Therapeutics Champions Brain Health During Alzheimer’s & Brain Awareness Month - Financial Post
- 6 weeks ago - Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month - GlobeNewsWire
- 7 weeks ago - Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 - GlobeNewsWire
- 2 months ago - Axsome initiated with an Outperform at Oppenheimer on revenue boost - Seeking Alpha